NRX Pharmaceuticals (NRXP) FCF Margin (2025 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly FCF Margin came in at 402.62% in Q1 2026, down 4.22% on a QoQ basis from 386.33% in Q4 2025.
NRX Pharmaceuticals (NRXP) FCF Margin (2025 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 2 years of FCF Margin data on file, last reported at 402.62% in Q1 2026.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 402.62% in Q1 2026; TTM through Mar 2026 was 670.26%, a N/A change from a year earlier, with the FY2025 full-year figure at 1175.0%, changed N/A from the prior year.
- FCF Margin for Q1 2026 stood at 402.62%, down from 386.33% in the prior quarter.
- Over the last five years, FCF Margin for NRXP reached as high as 386.33% in Q4 2025 and fell as low as 1445.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 472.06 Bn | 467.27 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 122.10 Bn | 114.85 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.25 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.50 Bn | 959.66 Mn | 4.17% |
| 10 | NRX Pharmaceuticals | 116.33 Mn | 109.63 Mn | 437,000.00 | -402.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -402.62% |
| Dec 31, 2025 | -386.33% |
| Sep 30, 2025 | -1,445.50% |